1 Type 1 Diabetes: Executive Summary
1.1 Type 1 Diabetes therapeutics market will grow to $9.91 billion by 2033
1.2 T1D market leaders employ diverse strategies to protect insulin franchises from biosimilar threats, while emerging players focus on disease-modifying innovations
1.3 Persistent unmet needs highlight gaps in current and emerging T1D therapies
1.4 The synergistic rise of pumps, CGMs, and ultra-rapid-acting insulins in T1D management
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers for monitoring the islet autoreactivity of T1D
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of T1D - 7MM
4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of T1D
4.4.5 Diagnosed prevalent cases of T1D segmented by BMI
4.4.6 Diagnosed prevalent cases of T1D that experienced hypoglycemic events
4.4.7 Diagnosed prevalent cases of T1D with brittle diabetes
4.4.8 Diagnosed prevalent cases of T1D that experienced DKA events
4.4.9 Diagnosed prevalent cases of T1D eligible for pancreas transplantation
4.4.10 Diagnosed prevalent cases of T1D with CKD
4.4.11 Diagnosed prevalent cases of T1D with CVD
4.4.12 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
4.4.13 Forecast assumptions and methods: total prevalent cases of T1D
4.5 Epidemiological forecast for T1D (2023-33)
4.5.1 Diagnosed prevalent cases of T1D
4.5.2 Age-specific diagnosed prevalent cases of T1D
4.5.3 Sex-specific diagnosed prevalent cases of T1D
4.5.4 Diagnosed prevalent cases of T1D by BMI category
4.5.5 Diagnosed prevalent cases of T1D that experienced hypoglycemic events
4.5.6 Diagnosed prevalent cases of T1D with brittle diabetes
4.5.7 Diagnosed prevalent cases of T1D that experienced DKA events
4.5.8 Diagnosed prevalent cases of T1D eligible for pancreas transplantation
4.5.9 Diagnosed prevalent cases of T1D with CKD
4.5.10 Diagnosed prevalent cases of T1D with CVD
4.5.11 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
4.5.12 Total prevalent cases of T1D
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 US disease management
5.3 5EU disease management
5.4 Japan disease management
5.5 KOL insights on disease management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Urgent need for disease-modifying therapies
7.3 Avoiding hypoglycemic episodes and optimising glycemic control
7.4 Improving compliance and reducing the burden of insulin therapy
7.5 High financial cost of T1D management
8 R&D Strategies
8.1 Overview
8.1.1 Immunomodulatory therapies: addressing autoimmune pathogenesis
8.1.2 Advanced drug delivery systems and glucose-responsive insulins
8.1.3 Regenerative medicine: pursuing curative therapies
8.2 Clinical trials design
8.2.1 Study design - adaptive clinical trials and comprehensive frameworks
8.2.2 Digital health integration
8.2.3 Model-based simulations
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
10.2.1 Insulin therapies
10.2.2 Non-insulin therapies
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Vice President of Disease Intelligence and Epidemiology
13.6.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- About the Analyst
- Contact the Publisher
List of Tables
Table 1: Type 1 Diabetes: key metrics in the 7MM
Table 2: Symptoms of T1D
Table 3: Diagnostic tests commonly used for T1D
Table 4: Risk factors and comorbidities for T1D
Table 5: Diagnostic tests and typical criteria for diagnosing T1D
Table 6: Treatment guidelines for T1D
Table 7: Top 10 deals by value, 2019-24
Table 8: T1D market - global drivers and barriers, 2023-33
Table 9: Key events impacting sales for T1D in the US, 2023-33
Table 10: T1D market - drivers and barriers in the US, 2023-33
Table 11: Key events impacting sales for T1D in the 5EU, 2023-33
Table 12: T1D market - drivers and barriers in the 5EU, 2023-33
Table 13: Key events impacting sales for T1D in Japan, 2023-33
Table 14: T1D market - drivers and barriers in Japan, 2023-33
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures
Figure 1: Global sales forecast by country for T1D in 2023 and 2033
Figure 2: Analysis of the company portfolio gap in T1D during the forecast period
Figure 3: Competitive assessment of the late-stage insulin and non-insulin treatments that the analyst expects to be licensed for the treatment of T1D during the forecast period
Figure 4: Etiology of T1D
Figure 5: Pathophysiology of T1D
Figure 6: 7MM, diagnosed prevalence of T1D, men and women, %, all ages, 2023
Figure 7: 7MM, total prevalence of T1D, men and women, %, all ages, 2023
Figure 8: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of T1D segmented by BMI category
Figure 10: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D that experienced hypoglycemia
Figure 11: 7MM, source used to forecast the diagnosed prevalent cases of T1D with brittle diabetes
Figure 12: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D that experienced DKA
Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of T1D that are eligible for a pancreas transplant
Figure 14: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D with CKD
Figure 15: 7MM, sources used and not used to forecast the diagnosed prevalent cases of T1D with CVD
Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
Figure 17: 7MM, sources used to forecast the total prevalent cases of T1D
Figure 18: 7MM, diagnosed prevalent cases of T1D, N, both sexes, all ages, 2023
Figure 19: 7MM, diagnosed prevalent cases of T1D by age, N, both sexes, 2023
Figure 20: 7MM, diagnosed prevalent cases of T1D by sex, N, all ages, 2023
Figure 21: 7MM, diagnosed prevalent cases of T1D by BMI category, N, both sexes, all ages, 2023
Figure 22: 7MM, diagnosed prevalent cases of T1D that experienced hypoglycemic events, N, both sexes, all ages, 2023
Figure 23: 7MM, diagnosed prevalent cases of T1D with brittle diabetes, N, both sexes, all ages, 2023
Figure 24: 7MM, diagnosed prevalent cases of T1D that experienced DKA, N, both sexes, all ages, 2023
Figure 25: 7MM, diagnosed prevalent cases of T1D eligible for pancreas transplantation, N, both sexes, =20 years,
Figure 26: 7MM, diagnosed prevalent cases of T1D with CKD, N, both sexes, all ages, 2023
Figure 27: 7MM, diagnosed prevalent cases of T1D with CVD, N, both sexes, all ages, 2023
Figure 28: 7MM, diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8, N, both sexes, all ages, 2023
Figure 29: 7MM, total prevalent cases of T1D, N, both sexes, all ages, 2023
Figure 30: Disease management flow chart
Figure 31: Unmet needs and opportunities in T1D
Figure 32: Overview of the development pipeline in T1D
Figure 33: Key late-stage trials for the promising pipeline agents that the analyst expects to be licensed for T1D in the 7MM during the forecast period
Figure 34: Competitive assessment of the pipeline insulin therapies benchmarked against the standard of care (SOC), Novolog (insulin aspart)
Figure 35: Competitive assessment of the pipeline non-insulin therapies benchmarked against the standard of care (SOC), Tzield (teplizumab)
Figure 36: Analysis of the company portfolio gap in T1D during the forecast period
Figure 37: Global (7MM) sales forecast by country for T1D in 2023 and 2033
Figure 38: Sales forecast by class for T1D in the US in 2023 and 2033
Figure 39: Sales forecast by class for T1D in the 5EU in 2023 and 2033
Figure 40: Sales forecast by class for T1D in Japan in 2023 and 2033
